Sensor Augmented - PAGE 2

What is the scientific evidence?

STAR 3 Study

30 Sites (U.S. and Canada)

• 485 type 1 patients   • 1 year study   • 6 month follow-up
Bergenstal RM, Tamborlane WV, Ahmann A, et. al. N Engl J Med. Doi: 10. 1056/NEJMoa1002853
 

What is the scientific evidence?

STAR 3 Study: Primary Endpoint (All Patients)

The Sensor Augmented Pump (SAP) group achieved a greater A1C reduction vs. the Multiple Daily Injections (MDI) group at 3 months and sustained it over 12 months.

Bergenstal RM, Tamborlane WV, Ahmann A, et. al. N Engl J Med. Doi: 10. 1056/NEJMoa1002853
 

What is the scientific evidence?

STAR 3 Study: A1C Reduction Correlates to Increased Sensor Use

  • The majority of patients used sensors ≥61% of the time
  • Patients who used sensors ≥81% of the time reduced their mean A1C by 1.2% at 1 year vs. baseline
Bergenstal RM, Tamborlane WV, Ahmann A, et. al. N Engl J Med. Doi: 10. 1056/NEJMoa1002853
 

What is the scientific evidence?

STAR 3 Study: Cumulative Events at 1 Year (All Patients)

No significant difference in severe hypoglycemia, DKA and weight change.

Bergenstal RM, Tamborlane WV, Ahmann A, et. al. N Engl J Med. Doi: 10. 1056/NEJMoa1002853
 

What is the scientific evidence?

STAR 3 Conclusions

Sensor augmented insulin pump therapy resulted in:

  • Overall A1C (mean) reduction 4x greater than MDI (0.8% v. 0.2%) for adults and pediatric patients from baseline to one year without an increase in severe hypoglycemia
Sensor Augmented Pump (SAP): from 8.3% to 7.5%
Multiple Daily Injections (MDI): from 8.3% to 8.1%

  • 1.0% AIC (mean) reduction in adults from baseline to one year
  • Patients wearing sensors ≥81% of the time reduced their mean A1C by 1.2% (reduction from baseline to one year)
  • Glycemic improvements were seen early (3 months) and were sustained at one year

Bergenstal RM, Tamborlane WV, Ahmann A, et. al. N Engl J Med. Doi: 10. 1056/NEJMoa1002853